Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Research team solves 40-year old mystery in leukemia treatment

Research team solves 40-year old mystery in leukemia treatment

A metabolic enzyme drives B cell lymphomas and could be a potential drug target

A metabolic enzyme drives B cell lymphomas and could be a potential drug target

Researchers investigate nelarabine drug for treating leukemia

Researchers investigate nelarabine drug for treating leukemia

Producing CAR T cell therapy at a lower cost

Producing CAR T cell therapy at a lower cost

Study takes new treatment approach for blood cancer

Study takes new treatment approach for blood cancer

Researchers discover new and improved way to treat poor-prognosis blood cancer

Researchers discover new and improved way to treat poor-prognosis blood cancer

Drama-based resources help Kingston University nursing students to cope with coronavirus pandemic

Drama-based resources help Kingston University nursing students to cope with coronavirus pandemic

Overcoming leukemia treatment resistance with nanoparticle drug delivery system

Overcoming leukemia treatment resistance with nanoparticle drug delivery system

Researchers call for caution of using CAR-T immunotherapy against AML

Researchers call for caution of using CAR-T immunotherapy against AML

Two potent small molecules appear to suppress tumor growth in multiple cancers

Two potent small molecules appear to suppress tumor growth in multiple cancers

Research team generates comprehensive developmental map of human T-cells

Research team generates comprehensive developmental map of human T-cells

Study shows how combining two drugs may be an effective treatment for HLH

Study shows how combining two drugs may be an effective treatment for HLH

Damon Runyon Cancer Research Foundation awards $3.2 million to early-career physician-scientists

Damon Runyon Cancer Research Foundation awards $3.2 million to early-career physician-scientists

Beta adrenergic agonists can help decrease risk of graft vs. host disease in alloBMT recipients

Beta adrenergic agonists can help decrease risk of graft vs. host disease in alloBMT recipients

Engineered natural killer cells show promise for treating a form of leukemia

Engineered natural killer cells show promise for treating a form of leukemia

Researchers confirm new therapeutic target for myelodysplastic syndrome

Researchers confirm new therapeutic target for myelodysplastic syndrome

New leukemia immune profiles predict drug resistance, positive responses to immunotherapy

New leukemia immune profiles predict drug resistance, positive responses to immunotherapy

DFG to establish ten new Collaborative Research Centers

DFG to establish ten new Collaborative Research Centers

New drug can prevent life-threatening anaphylaxis, shows study

New drug can prevent life-threatening anaphylaxis, shows study

Researchers discover key gene essential for survival of leukemia stem cells

Researchers discover key gene essential for survival of leukemia stem cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.